Rahul Winayak

@RWinayak

Postdoctoral Research Fellow in Kidney Cancer at City of Hope, Los Angeles

Joined July 2019

82 Following 103 Followers 80 Posts

Latest posts 5

Vote for @montypal for the ASCO Board. A mentor who tirelessly creates opportunities for early-career colleagues and brings a vision ASCO needs now more than ever: embracing AI, strengthening global collaborations, and expanding local opportunities for young investigators.

Sumanta K. Pal, MD, FASCO Verified account @montypal Oct 28

Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!

View quoted post on X

Rahul Winayak @RWinayak Oct 26

Incredible talk at #ESMO26 on reharnessing the historical success of interleukin therapy in RCC/melanoma through cytokine-armored T cell approaches.
🎯 Cytokine-armored CAR-T cells allow targeted delivery of cytokines and even T cell repurposing
@xrtcell

Rahul Winayak @RWinayak Oct 25

Novel targets in mRCC remain a critical unmet need, especially in the IO-resistance setting.
🎬Watch here as I explain MOAs of the most promising novel targets in early phase testing.
#ESMO26

Targeted Onc @TargetedOnc Oct 24

At #ESMO26, Rahul Winayak, MD (@cityofhope) explains new metastatic #RCC targets—GPR65, HPK1, ENPP3, CD70—that aim to overcome #immunotherapy resistance.

🎥 WATCH: targetedonc.com/view/rahul-win…

#KidneyCancer #Oncology | @RWinayak @CityofHope_GU

View quoted post on X

Rahul Winayak @RWinayak Oct 23

Thanks @OncLive for a great interview on my #ESMO26 abstract highlighting novel targets in mRCC. Excited to share the latest developments during Sunday's X takeover, including @montypal's presentation of initial Ph1 Xmab819 (ENPP3xCD3) data. 🚀

OncLive.com Verified account @OncLive Oct 23

Thank you to @RWinayak of @cityofhope for sharing insights from research on novel target expressions in renal cell carcinoma, being presented at @myESMO #ESMO26

View quoted post on X

Rahul Winayak @RWinayak Oct 23

Excited to share our #ESMO26 abstract on emerging targets in mRCC. Analysis of 2,134 RCC transcriptomes identified immunogenic (GPR65/HPK1) and angiogenic (ENPP3/CD70) programs linked to improved outcomes with IO vs non-IO therapy, informing future combination strategies.